A Phase 3 interventional study of Canvuparatide and Placebo in Hypoparathyroidism, sponsored by MBX Biosciences. Recruiting at 22 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by MBX Biosciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Hypoparathyroidism with a site in United States — 8 open to participants now, 12 under way, 5 of them phase 3. Hypoparathyroidism · United States.
Among the 43 studies in Hypoparathyroidism with a site in United States, this one is the 2nd largest by planned enrollment of the 34 interventional ones that give a count, is one of 6 that started in 2026, is one of 13 in phase 3, reaches primary completion later than 5 of the 11 other live ones, and was the 42nd registered.
128 studies on the registry are indexed under Hypoparathyroidism; 30 are open to participants now.
Browse Hypoparathyroidism studies →8 of the 43 studies in Hypoparathyroidism with a site in United States are open now. Recruiting first, the newest first:
Bettina Mittendorfer · Sites in United States
Ages 18–100 · Healthy volunteers
Calcilytix Therapeutics, Inc., a BridgeBio company · Sites in United States, Canada, Japan
Ages 16+
Ascendis Pharma Bone Diseases A/S · Sites in United States
Ages 18+
Ascendis Pharma A/S · Sites in United States
Ages 18–50 · Women only
Ascendis Pharma A/S · Sites in United States
Ages 15–50 · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 26 Hypoparathyroidism studies recruiting now, 19 (73%) set no upper age limit and 5 (19%) stop at 75 or younger; 5 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 12 · Phase 3 14 · Phase 4 3
First in 1991; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 160 is above the median of 50 across 77 interventional studies indexed under Hypoparathyroidism.
Median enrollment 41 across the 34 interventional studies, 95 across the 9 observational. Of the 29 that completed or were terminated, 22 (76%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 43 have an industry lead sponsor. The 10 most frequent:
MBX Biosciences is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
MBX Biosciences has 3 studies filed under Hypoparathyroidism — fewer than ten, so there is no comparison to draw.
3 of the studies in Hypoparathyroidism with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07081997Phase 3Ascendis Pharma Bone Diseases A/SA Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism | 2027-06 |
| NCT05793853Columbia UniversityHypoparathyroidism Natural History Study | 2026-12 |
| NCT07264634Ascendis Pharma A/SA Study to Assess the Amount of Palopegteriparatide in Breast Milk of Lactating Females Requiring YORVIPATH® (Palopegteriparatide) | 2027-08 |
Add all 3 to your calendar (.ics) → With an account.
Among the 43 studies in Hypoparathyroidism with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate the efficacy and safety of canvuparatide administered as a once-weekly (QW) treatment to adult study participants with hypoparathyroidism (HypoPT).
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Canvuparatide is provided as an integral drug-device combination product (DDC) intended for single-use administration, to deliver 1mL of canvuparatide via a manual SC injection. Dosing is once weekly.
Drug: Canvuparatide
Placebo is provided as an integral drug-device combination product (DDC) intended for single-use administration, to deliver 1mL of placebo via a manual SC injection. Dosing is once weekly.
Other: Placebo
• Drug per vial: Each DDC contains 1 vial of lyophilized drug product. The reconstituted strengths are 400 μg/mL, 600 μg/mL, 800 μg/mL, 1000 μg/mL, 1200 μg/mL, 1400 μg/mL, and 1600 μg/mL.
Also known as: MBX 2109
• Drug per vial: Each DDC contains 1 vial of lyophilized drug product. The reconstituted strengths are 400 μg/mL, 600 μg/mL, 800 μg/mL, 1000 μg/mL, 1200 μg/mL, 1400 μg/mL, and 1600 μg/mL.
To evaluate the effect of pooled weekly doses of canvuparatide on the proportion of responder patients at week 26.
Responder status is defined as a study participant who meets the following composite criteria: * Independence from active vitamin D * Independence from therapeutic doses of calcium (standing elemental calcium dose of ≤ 600 mg/day) * 2 consecutive albumin-adjusted serum calcium results in the normal range (8.3-10.6 mg/dL) (2.07-2.64 mmol/L) * No increase in study drug
Time frame: 26 Weeks
Started Aug 2026 (actual). Primary completion is estimated for Jan 2028, 17 months after the start.
Of 15 phase 3 interventional studies under Hypoparathyroidism, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 86. This study's planned 17 months is close to that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Canvuparatide
MBX Biosciences